Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and μ-opioid receptor binding in the basal ganglia

Experimental Brain Research

Volumn 130, Issue 2, 2000, Pages 142-150

  Page, Keith J ^a,c   Besret, Laurent ^a   Jain, Meena ^a   Monaghan, Eimear M ^a   Dunnett, Stephen B ^a   Everitt, Barry J ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UK   (United Kingdom)

^c Pharmagene Laboratories Ltd   (United Kingdom)

Author keywords

Huntington's disease; Neurodegeneration; Receptor autoradiography; Striatonigral; Striosome matrix

Indexed keywords

3 NITROPROPIONIC ACID; CANNABINOID RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MU OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; GLOBUS PALLIDUS; HUNTINGTON CHOREA; MALE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SUBSTANTIA NIGRA;

EID: 0033973053     PISSN: 00144819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002210050016     Document Type: Article

References (60)

1. Andrew SE, Goldberg YP, Kremer B, Telenius H, Thielmann J, Adam S, Starr E, Squittieri F, Lin B, Kalchman MA, Graham RK, Hayden MR (1993) The relationship between trinucleotide repeat (CAG) length and clinical features of Huntington's disease. Nature Gen 4:398-403
2. Araujo DM, Hilt DC (1998) Glial cell line derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid. Neuroscience 82:117-127
3. Arvidsson U, Riedl M, Chakrabarti S, Lee J-H, Nakano AH, Dado RJ, Loh HH, Law PY, Wessendorf MW, Elde R (1995) Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J Neurosci 15:3328-3341
4. Augood SJ, Faull RLM, Love DR, Emson PC (1996) Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience 72:1023-1036
5. Augood SJ, Faull RLM, Emson PC (1997) Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 42:215-221
6. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characterisation of Huntington's disease by quinolinic acid. Nature 321:168-171
7. Beal MF, Kowall NW, Swartz KJ, Ferrante RJ, Martin JB (1989) Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions. Synapse 3:38-47
8. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW (1991) Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 11:1649-1659
9. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993) Neurochemical and histologic characterisation of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:4181-4192
10. Boegman RJ, Smith Y, Parent A (1987) Quinolinic acid does not spare striatal neuropeptide Y-immunoreactive neurons. Brain Res 415:178-182
11. Borlongan CV, Koutouzis TK, Freeman TB, Cahill DW, Sanberg PR (1995) Behavioural pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. Brain Res 697:254-257
12. Borlongan CV, Koutouzis TK, Sanberg PR (1997) 3-Nitropropionic acid animal model of Huntington's disease. Neurosci Biobehav Rev 21:289-293
13. Brasted PJ, Humby T, Dunnett SB, Robbins TW (1997) Unilateral lesions of the dorsal striatum in rats disrupt responding in egocentric space. J Neurosci 17:8919-8926
14. Browne SE, Bowling AC, MacGarvery U, Baik MJ, Muqit MMK, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington's disease - selective vulnerability of the basal ganglia. Ann Neurol 41:646-653
15. Davies SW, Roberts PJ (1987) No evidence for preservation of somatostatin-containing neurons after intrastriatal injections of quinolinic acid. Nature 327:326-329
16. Davies SW, Roberts PJ (1988) Sparing of cholinergic neurons following quinolinic acid lesions of the rat striatum. Neuroscience 26:387-393
17. Davies SW, Turmaine M, Cozens BA, diFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537-548
18. Davies SW, Beardsall K, Turmaine M, diFiglia M, Aronin N, Bates GP (1998) Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine expansion. Lancet 351:131-133
19. diFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of Huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993
20. Donoghue JP, Herkenham M (1986) Neostriatal projections from individual cortical fields conform to histochemically distinct striatal compartments in the rat. Brain Res 365:397-403
21. Dunnett SB, Kendall AL, Watts C, Torres EM (1997) Neuronal transplantation for Parkinson's and Huntington's diseases. Br Med Bull 53:757-776
22. Ellison DW, Beal MF, Mazurek MF, Malloy JR, Bird ED, Martin JB (1987) Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease. Brain 110:1657-1673
23. Figueredo-Cardenas G, Anderson KD, Chen Q, Veenman CL, Reiner A (1994) Relative survival of striatal projection neurons after intrastriatal injection of quinolinic acid in rats. Exp Neurol 129:37-56
24. Figueredo-Cardenas G, Chen Q, Reiner A (1997) Age-dependent differences in survival of striatal somatostatin-NPY-NADPH- diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats. Exp Neurol 146:444-457
25. Figueredo-Cardenas G, Harris CL, Anderson KD, Reiner A (1998) Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types. Exp Neurol 149:356-372
26. Furtado JC, Mazurek MF (1996) Behavioural characterisation of quinolinate-induced lesions of the medial striatum: relevance to Huntington's disease. Exp Neurol 138:158-168
27. Gerfen CR (1992) The neostriatal mosaic: multiple levels of compartmental organisation. Trends Neurosci 4:133-139
28. Glass M, Faull RLM, Dragunow M (1993) Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 56:523-527
29. Glass M, Dragunow M, Faull RLM (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299-318
30. Guyot MC, Palfi S, Stutzmann J-M, Maziere M, Hantraye P, Brouillet E (1997) Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience 81:141-149
31. Hamilton BF, Gould DH (1987) Correlation of morphologic brain lesions with physiologic alterations and blood brain barrier impairment in 3-nitropropionic acid toxicity in rats. Acta Neuropathol (Berl) 74:67-74
32. Hedreen JC, Folstein SE (1995) Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol 54:105-120
33. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localisation in brain. Proc Natl Acad Sci U S A 87:1932-1936
34. Herkenham M, Lynn AB, Ross Johnson M, Melvin LS, de Costa BR, Rice KC (1991a) Characterisation and localisation of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583
35. Herkenham M, Lynn AB, de Costa BR, Richfield EK (1991b) Neuronal localisation of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547:267-274
36. Huntingtons Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983
37. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR (1993) Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Ann Neurol 43:2689-2695
38. Kaneko T, Minami M, Satoh M, Mizuno N (1995) Immunocytochemical localisation of mu-opioid receptor in the rat caudate putamen. Neurosci Lett 184:149-152
39. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF (1997) Energy metabolism defects in Huntington's disease and effects of co-enzyme Q10. Ann Neurol 41:160-165
40. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M (1991) 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 18:492-498
41. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1987) Autoradiographic differentiation of Mu, Delta and Kappa opioid receptors in the rat forebrain and midbrain. J Neurosci 7:2445-2464
42. Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K, Singaraja R, Kazemi-Esfarjani P, Devon R, Kim SU, Bredesen DE, Tufaro F, Hayden MR (1998) Length of huntingtin and its polyglutamine tract influences localisation and frequency of intranuclear aggregates. Nature Gen 18:150-154
43. Mathews RT, Yang LC, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurahdaouk R, Beal MF (1998) Neuroprotective effects of creatinine and cyclocreatinine in animal models of Huntington's disease. J Neurosci 18:156-163
44. Morton AJ, Nicholson LFB, Faull RLM (1993) Compartmental loss of NADPH diaphorase from the neuropil of the human striatum in Huntington's disease. Neuroscience 53:159-168
45. Nishino H, Shimano Y, Kumazaki M, Sakurai T (1995) Chronically administered 3-nitropropionic acid induces striatal lesions attributed to dysfunction of the blood-brain barrier. Neurosci Lett 186:161-164
46. Nishino H, Kumazaki M, Fukada A, Fujimoto I, Shimano Y, Hida T, Deshpande SB, Shimizu H, Morikawa S, Inubushi T (1997) Acute 3-nitropropionic acid intoxication induces astrocytic cell death and dysfunction of the blood-brain barrier: involvement of dopamine toxicity. Neurosci Res 27:343-355
47. Page KJ, Dunnett SB (1998) The effect of systemic 3-nitropropionic acid induced neurotoxicity on the expression and activity of cytochrome oxidase and succinate dehydrogenase mRNAs. Neuroreport 9:2881-2886
48. Palfi S, Ferrante RJ, Brouillet E, Beal MF, Dolan R, Guyot MC, Peschanski M, Hantraye P (1996) Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J Neurosci 16:3019-3025
49. Penney JB, Vonsattel JP, MacDonald ME, Gusella JF, Myres RH (1997) CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41:689-692
50. Pert CB, Kuhar MJ, Snyder SH (1976) Opiate receptor: autoradiographic localization in rat brain. Proc Natl Acad Sci U S A 73:3729-3733
51. Reynolds DS, Morton AJ (1998) Changes in blood-brain barrier permeability following neurotoxic lesions of the rat brain can be visualised with trypan blue. J Neurosci Methods 79:115-121
52. Richfield EK, Herkenham M (1994) Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 36:577-584
53. Saporta S, Cameron DF, Borlongan CV, Sanberg PR (1998) Survival of rat and porcine Sertoli cell transplants in the rat striatum without cyclosporin-A immunosuppression. Exp Neurol 146:299-304
54. Sato S, Gobbel GT, Honkaneimi J, Li YB, Kondo T, Murakami K, Sato M, Copin JC, Chan PH (1997a) Apoptosis in the striatum of rats following intraperitoneal injection of 3-nitropropionic acid. Brain Res 745:343-347
55. Sato S, Gobbel GT, Li Y, Kondo T, Murakami K, Sato M, Hasegawa K, Copin JC, Honkaniemi J, Sharp FR, Chan PH (1997b) Blood-brain-barrier disruption, HSP70 expression and apoptosis due to 3-nitropropionic acid, a mitochondrial toxin. Acta Neurochir Suppl (Wien) 70:237-239
56. Shear DA, Dong J, Haik-Kruger KL, Bazzett TJ, Albin RL, Dunbar GL (1998) Chronic administration of quinolinic acid in the rat striatum causes spatial learning deficits in a radial arm water maze task. Exp Neurol 150:305-311
57. Tsai MJ, Goh CC, Wan YL, Chang C (1997) Metabolic alterations produced by 3-nitropropionic acid in rat striata and cultured astrocytes: quantitative in vitro 1H-nuclear magnetic resonance spectroscopy and biochemical characterisation. Neuroscience 79:819-826
58. Vonsattel J-P, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP (1985) Neuropathological classification of Huntington's disease. Neuropathol Exp Neurol 44:559-577
59. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization study of normal aged and Alzheimer brains. Neuroscience 63:637-652
60. Zeevalk GD, Derr-Yellin E, Nicklas WJ (1995) NMDA receptor involvement in toxicity to dopamine neurons in vitro caused by the succinate dehydrogenase inhibitor 3-nitropropionic acid. J Neurochem 64:455-458